Impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in a population-based cohort of head and neck cancer patients receiving high-dose cisplatin chemotherapy

2014 ◽  
Vol 12 (11) ◽  
pp. 394-400
Author(s):  
Serge Makarenko ◽  
George Dranitsaris ◽  
Renata Peixoto ◽  
Jenny Ruan ◽  
Winson Cheung
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Dose Intensity ◽  
Population Based ◽  
High Dose ◽  
Recurrence Free Survival ◽  
Free Survival

scholarly journals Less is Enough: Outcome of Bimodality Definitive Concurrent Chemoradiation does not Differ from that of Trimodality Upfront Neck Dissection Followed by Adjuvant Treatment for >6 cm Bulky Lymph Node (N3) Head and Neck Cancer

2019 ◽  
Author(s):  
Wan-Yu Chen ◽  
Tseng-Cheng Chen ◽  
Shih-Fan Lai ◽  
Tony Hsiang-Kuang Liang ◽  
Bing-Shen Huang ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Dissection ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Primary Tumor ◽  
Treatment Modalities ◽  
Recurrence Free Survival ◽  
Tumor Treatment ◽  
Free Survival

Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are lacking. This study aimed to compare the treatment outcomes between definitive concurrent chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. 93 N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT can achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Cautions should be made to avoid overtreatment for this group of patients.

End-of-life care for head and neck cancer patients: a population-based study

2016 ◽  
Vol 25 (5) ◽  
pp. 1529-1536 ◽  
Author(s):  
Tzu-Lung Kuo ◽  
Ching-Heng Lin ◽  
Rong-San Jiang ◽  
Ting-Ting Yen ◽  
Chen-Chi Wang ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
End Of Life ◽  
Cancer Patients ◽  
Neck Cancer ◽  
End Of Life Care ◽  
Population Based ◽  
Life Care ◽  
Population Based Study

Predicitve factors of cisplatin (CDDP) discontinuation in concurrent chemoradiotherapy (CCRT) to locally advanced head and neck cancer patients.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e17006-e17006
Author(s):  
Kenji Nakano ◽  
Yasuyoshi Sato ◽  
Yukiko Sato ◽  
Takashi Toshiyasu ◽  
Takao Asari ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Renal Dysfunction ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Odds Ratio ◽  
Locally Advanced ◽  
Stage Iv ◽  
High Dose ◽  
Advanced Head

e17006 Background: CCRT is a standard therapy for locally advanced head and neck cancer patients, but some patients have intolerance to high dose density of CDDP. Predictive factors for CDDP discontinuation need to be investigated for making appropriate treatment decisions. Methods: We retrospectively analyzed nonmetastatic head and neck cancer patients treated with CCRT with CDDP (80 mg/m2 per 3 weeks) from November 2005 to April 2012 in our institute. Radiation therapy was performed as three-dimensional radiotherapy or intensity-modified radiotherapy (IMRT). Results: A total of 164 patients received CCRT, of which 89 (54 %) were Stage IV;. Primary sites were as follows; oral cavity 7, oropharynx 52, hypopharynx 53, larynx 14, nasopharynx 30, paranasal sinus/nasal cavity 3, and unknown primary 5. IMRT was performed to 54 (33 %) patients. Median follow-up time was 19 months (range 1-69 months); 1-year overall survival (OS) and progression free survival (PFS) were 90 % and 78 %. Non-Stage IV; and high creatinine clearance (>70 ml/min) were associated with longer OS in Cox proportional hazard model. As for CDDP treatment, 75 (46 %) patients completed 3 cycles of CDDP, 69 (42 %) patients received 2 cycles, and 20 (12 %) patients received only 1 cycle. The main reasons for CDDP discontinuation were infection (24 patients) and renal dysfunction (18 patients). In logistic regression analysis, male sex, younger age (< 61 years) and high body mass index (BMI) (>25) were associated with 3 cycles completion of CDDP statistically significantly (p = .002, odds ratio 6.622; p = .006, odds ratio 2.602; p = .035, odds ratio 2.655, respectively). Conclusions: In CCRT to head and neck cancer patients, infection and renal dysfunction were the main reasons for CDDP discontinuation. Sex, age and BMI could be predictive of CDDP completion/discontinuation.

scholarly journals Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer

Oncogenesis ◽  
2015 ◽  
Vol 4 (4) ◽  
pp. e147-e147 ◽  
Author(s):  
S S Chauhan ◽  
J Kaur ◽  
M Kumar ◽  
A Matta ◽  
G Srivastava ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Protein Expression ◽  
Head And Neck ◽  
Neck Cancer ◽  
Recurrence Free Survival ◽  
Free Survival

Oral Pain in the Cancer Patient

2019 ◽  
Vol 2019 (53) ◽  
Author(s):  
Joel B Epstein ◽  
Christine Miaskowski
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Oral Mucositis ◽  
Molecular Mechanisms ◽  
Management Practices ◽  
Opioid Analgesics ◽  
High Dose ◽  
Oral Pain

Abstract Oral pain due to cancer and associated treatments is common. The prevalence and severity of oral cancer is high. Painful oral mucositis develops in head and neck cancer patients following surgery and associated radiation therapy and/or chemotherapy. In addition, oral pain, including pain from mucositis, occurs in patients receiving chemotherapy for cancers of the hematopoietic system and cancers at other anatomic sites. Despite pain management practices that include high-dose opioid analgesics, patients rarely obtain relief from either head and neck cancer pain or mucositis pain. Because oral pain in cancer patients is likely due to both nociceptive and neuropathic mechanisms, effective management of pain requires treatments for both processes. As knowledge of the pathophysiology of oral pain in cancer patients increases, new approaches for the prevention and management are anticipated. This article focuses on the emerging evidence that supports the molecular mechanisms and the unique oral micro-neuroanatomy that in combination produce the severe oral pain experienced by cancer patients. In addition, this article summarizes the current state of clinical management of oral mucositis pain.

Sign in / Sign up

Export Citation Format

Share Document